Changes in Hong Kong stocks | Pharma Ming Kangde (02359) rose more than 3% and was recently removed from the US 1260H List. The company has a leading edge in the field of chemical drug CDMO

The Zhitong Finance App learned that Yao Ming Kangde (02359) rose more than 3%. As of press release, it had risen 3.56% to HK$203.6, with a turnover of HK$767 million.

According to the news, Yao Ming Kangde recently announced that the company learned that the Ministry of National Defense decided to remove Yao Ming Kangde from the CMC list under 1260H. The Deputy Minister of Defense determined that the court's order approving the company's preliminary injunction motion should be removed from the Ministry of Defense's updated 1260H list. Lyon believes that this move is expected to further mitigate the company's geopolitical risks, and continues to regard Pharmaceutical Kangde as one of the core holdings of the global healthcare portfolio.

Citi released a research report stating that the company was included in the 90-day upward catalyst observation. In the CRO/CDMO industry, Yao Ming Kangde has leading advantages in talent, technology and production capacity, which helps attract more customers and further expand the business. The bank believes that cell and gene therapy CDMO services and PROTAC technology are the company's main growth drivers in the future, and the relevant potential is still underestimated by the market. Furthermore, it is expected that China Laboratory Services will achieve strong sales growth with the support of long-tail strategies and innovative platforms.